Commitment COM-281
Post-approval commitment for FDA-2024-0081. Category: Risk Management. Priority: medium.
Commitment ID
COM-281
Application
Authority
Food and Drug Administration
Category
Risk Management
Priority
medium
Status
Overdue
Due Date
2025-01-27
Completed At
—
Owner
Sarah Chen
Created
2022-08-16
Description
Complete Phase IV post-marketing observational study (n=500)
Evidence (0)
No evidence documents attached. Upload evidence to mark this commitment as complete.